Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Amarin Corp PLC (AMRN) Insider Trading Activity
Healthcare • Drug Manufacturers - General • 275 employees
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Total Value
-$94,859.38
Total Shares
124,501
Average Trade Value
-$5,928.71
Most Active Insider
Ketchum Steven B
Total Activity: $57,973
Largest Single Transaction
$17,597
by Berg Aaron on Jan 30, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Scientific Officer
|
Jan 31, 2025 | 38,667 | $0 | 768,094 (+5.0%) | Exercise/Conversion | |
|
Svp, CFO
|
Jan 31, 2025 | 36,667 | $0 | 93,573 (+39.2%) | Exercise/Conversion | |
|
Svp, CFO
|
Jan 31, 2025 | 20,189 | $12,517 | 73,384 (-27.5%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Jan 31, 2025 | 24,833 | $15,396 | 729,427 (-3.4%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Jan 31, 2025 | 34,566 | $0 | 728,524 (+4.7%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Jan 31, 2025 | 44,933 | $0 | 754,260 (+6.0%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Jan 31, 2025 | 21,093 | $13,078 | 747,001 (-2.8%) | Payment of Exercise Price | |
|
Svp, CFO
|
Jan 31, 2025 | 8,400 | $0 | 56,562 (+14.9%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Jan 31, 2025 | 19,197 | $11,902 | 709,327 (-2.7%) | Payment of Exercise Price | |
|
Svp, CFO
|
Jan 31, 2025 | 4,665 | $2,892 | 51,897 (-9.0%) | Payment of Exercise Price | |
|
Svp, CFO
|
Jan 31, 2025 | 11,267 | $0 | 63,164 (+17.8%) | Exercise/Conversion | |
|
Svp, CFO
|
Jan 31, 2025 | 6,258 | $3,880 | 56,906 (-11.0%) | Payment of Exercise Price | |
|
President and CEO
|
Jan 30, 2025 | 51,500 | $0 | 856,880 (+6.0%) | Exercise/Conversion | |
|
President and CEO
|
Jan 30, 2025 | 28,382 | $17,597 | 828,498 (-3.4%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Jan 30, 2025 | 28,382 | $17,597 | 693,958 (-4.1%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Jan 30, 2025 | 51,500 | $0 | 722,340 (+7.1%) | Exercise/Conversion |